Genital Herpes - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 57 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Genital Herpes - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Genital Herpes - Pipeline Review, H2 2014', provides an overview of the Genital Herpes's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Genital Herpes
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Genital Herpes and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Genital Herpes pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Genital Herpes
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Genital Herpes Overview 7
Therapeutics Development 8
Pipeline Products for Genital Herpes - Overview 8
Pipeline Products for Genital Herpes - Comparative Analysis 9
Genital Herpes - Therapeutics under Development by Companies 10
Genital Herpes - Therapeutics under Investigation by Universities/Institutes 11
Genital Herpes - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Genital Herpes - Products under Development by Companies 14
Genital Herpes - Products under Investigation by Universities/Institutes 15
Genital Herpes - Companies Involved in Therapeutics Development 16
Vical Incorporated 16
Agenus, Inc. 17
NanoViricides, Inc. 18
Starpharma Holdings Limited 19
Foamix Ltd. 20
AiCuris GmbH & Co. KG 21
Genital Herpes - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
HerpV Vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
pritelivir - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
astodrimer - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
VCLHB-01 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
VCLHM-01 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
HerpeCide-I - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
HSV-2 Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
acyclovir - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
genital herpes vaccine [HSV-2] - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
herpes simplex vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Genital Herpes - Recent Pipeline Updates 41
Genital Herpes - Dormant Projects 46
Genital Herpes - Discontinued Products 47
Genital Herpes - Product Development Milestones 48
Featured News & Press Releases 48
Jun 26, 2014: Agenus Vaccine Shows Significant Reduction in Viral Burden After HerpV Generated Immune Activation 48
Nov 07, 2013: Agenus' HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 Trial 49
Oct 17, 2013: ALLIED HERPES PHASE I TRIAL PROGRESS UPDATE 50
Jun 19, 2013: Allied Healthcare Receives Ethical Approval To Commence Phase I Clinical Trial Of HSV-2 Vaccine 50
Feb 27, 2013: Agenus's HerpV Phase II Study To Treat Genital Herpes Completes Enrollment 51
Jan 29, 2013: AiCuris Surpasses 50% Enrollment Milestone In Phase II Trial For Herpes Drug Pritelivir 52
Nov 27, 2012: AiCuris Starts Second Clinical Efficacy Trial With pritelivir 52
Oct 23, 2012: Agenus Commences Phase II Study Of HerpV Vaccine For Treatment Of Genital Herpes 53
Aug 07, 2012: AiCuris To Present Data On AIC316 At International Herpesvirus Workshop 54
Apr 16, 2012: AiCuris To Report AIC316 Phase II trial Data At International Meetings 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57

List of Tables
Number of Products under Development for Genital Herpes, H2 2014 8
Number of Products under Development for Genital Herpes - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Genital Herpes - Pipeline by Vical Incorporated., H2 2014 16
Genital Herpes - Pipeline by Agenus, Inc., H2 2014 17
Genital Herpes - Pipeline by NanoViricides, Inc., H2 2014 18
Genital Herpes - Pipeline by Starpharma Holdings Limited, H2 2014 19
Genital Herpes - Pipeline by Foamix Ltd., H2 2014 20
Genital Herpes - Pipeline by AiCuris GmbH & Co. KG, H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Genital Herpes Therapeutics - Recent Pipeline Updates, H2 2014 41
Genital Herpes - Dormant Projects, H2 2014 46
Genital Herpes - Discontinued Products, H2 2014 47